There is no doubt that VKAs (Warfarin) have been used since over 50 years for the management of stroke prevention in Non-Valvular Atrial Fibrillation and Venous Thromboembolism. However, the emergence of non-vitamin K oral anticoagulants such as Pradaxa, Xarelto, Eliquis and Lixiana have changed the landscape of thromboprophylaxis.